Determine the necessary mass, volume, or concentration for preparing a solution.
BMVC - ≥99% , CAS No.627810-06-4
注文可能
グレード＆純度 ≥99%
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
このグレードを選ぶ理由
≥99% ベースライン干渉を最小限に抑える必要がある、感度の高いクロマトグラフィーおよび分析ワークフロー向け。
保管・配送
Store at -20°C Ice chest + Ice pads に出荷。正確な仕様については、ロット固有の COA をご確認ください。
品質書類
SDS、COA、データシート、仕様書をダウンロードできます。ロット固有の COA はロット番号検索で入手可能です。
文献的裏付け
クロマトグラフィー、有機合成、クロスカップリング反応に関する 0 件の査読済み論文で引用されています。
概要
BMVC is a potent G-quadruplex (G4) stabilizer and a selective telomerase inhibitor with an IC 50 of ~0.2 μM. BMVC inhibits Taq DNA polymerase with an IC 50 of ~2.5 μM. BMVC increases the melting temperature of G4 structure of telomere and accelerates telomere length shortening. Anticancer activities
In Vitro
BMVC (0.5 μM; 0-18 days; H1299 cells) treatment markedly increases the percentage of sub-G1-phase cells after 18 days. BMVC (0.5 μM; 0-18 days; H1299 cells) long-term treatment leads to ceasing of cell growth and eventually cell death through apoptosis. The long-term BMVC treatment induces senescence program in H1299 cells. In BMVC-treated cancer cells, hallmarks of senescence, including morphologic changes, detection of senescence-associated β-galactosidase activity, and decreasesd bromodeoxyuridine incorporation, are detected. The BMVC-induced senescence phenotype is accompanied by progressive telomere shortening and detection of the DNA damage foci, indicating that BMVC caused telomere uncapping after long-term treatments. BMVC also suppresses the tumor-related properties of cancer cells, including cell migration, colony-forming ability, and anchorage-independent growth. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cycle AnalysisCell Line: H1299 cells Concentration: 0.5 μM Incubation Time: 0 day, 6 days, 12 days, 18 days Result: The percentage of sub-G1-phase cells was markedly increased after 18 days. Apoptosis AnalysisCell Line: H1299 cells Concentration: 0.5 μM Incubation Time: 0 day, 6 days, 12 days, 18 days Result: Increased apoptotic cells.
In Vivo
BMVC (1 mg/kg; intraperitoneal injection; every 3 day; BALB/cAnN.Cg-Foxn1 nu /CrlNarl mice) treatment delays tumorigenic potential of cancer cells in vivo . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: BALB/cAnN.Cg-Foxn1 nu /CrlNarl mice injected with H1299 cells Dosage: 1 mg/kg Administration: Intraperitoneal injection; every 3 day Result: The growth rates of tumors in animals were significantly slower than that of control animals. The tumor cells of the mice were indeed entering apoptosis.
Form:Solid
IC50& Target:IC50: ~0.2 μM (Telomerase), G-quadruplex, IC50: ~2.5 μM (Taq DNA polymerase)
仕様
仕様と純度
≥99%
生化学的・生理学的メカニズム
BMVC is a potent G-quadruplex (G4) stabilizer and a selective telomerase inhibitor with an IC 50 of ~0.2 μM. BMVC inhibits Taq DNA polymerase with an IC 50 of ~2.5 μM. BMVC increases the melting temperature of G4 structure of telomere and accelerates telo
保管条件
Store at -20°C
入荷
Ice chest + Ice pads
この製品は冷冷この冷このこの製品の運送が必要です。地上およびその他の経済サービスは利用できません。
アクションタイプ
INHIBITOR
純度
≥99%
名前と識別子
分子量
657.33
ドキュメント
📋 安全データシート（SDS）
危険性、取扱い、保管、および規制遵守を網羅した包括的な文書。
<<<<<<< HEAD SDS をダウンロード → ======= SDS をダウンロード → >>>>>>> release248-p3詳細データ
証明書（CoA、COO、BSE/TSEと分析図）
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
ソリューション計算機
レビュー
顧客レビュー
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corporation. All rights reserved.